CN103897037B - 特异性结合前列腺癌的短肽及其应用 - Google Patents
特异性结合前列腺癌的短肽及其应用 Download PDFInfo
- Publication number
- CN103897037B CN103897037B CN201410115439.9A CN201410115439A CN103897037B CN 103897037 B CN103897037 B CN 103897037B CN 201410115439 A CN201410115439 A CN 201410115439A CN 103897037 B CN103897037 B CN 103897037B
- Authority
- CN
- China
- Prior art keywords
- phage
- prostate cancer
- cell
- lncap
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 39
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 36
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 35
- 230000009870 specific binding Effects 0.000 title claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 23
- 229920001184 polypeptide Polymers 0.000 abstract description 22
- 238000012216 screening Methods 0.000 abstract description 22
- 108010067902 Peptide Library Proteins 0.000 abstract description 9
- 230000027455 binding Effects 0.000 abstract description 9
- 238000012917 library technology Methods 0.000 abstract description 4
- 238000011835 investigation Methods 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 238000003759 clinical diagnosis Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 30
- 238000000034 method Methods 0.000 description 11
- 238000005406 washing Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 101100351213 Chromobacterium violaceum (strain ATCC 12472 / DSM 30191 / JCM 1249 / NBRC 12614 / NCIMB 9131 / NCTC 9757) pcp gene Proteins 0.000 description 3
- 101100126615 Mus musculus Itpr1 gene Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 101150075058 pcp1 gene Proteins 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000207 volumetry Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
筛选次数 | 加入噬菌体数(pfu) | 回收噬菌体数(pfu) | 回收率 |
1 | 1011 | 102 | 10-9 |
2 | 1011 | 102 | 10-9 |
3 | 1011 | 104 | 10-7 |
4 | 1011 | 105 | 10-6 |
Claims (4)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610112193.9A CN105566455A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp13及其应用 |
CN201610112231.0A CN105601717A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp15及其应用 |
CN201610110725.5A CN105541973A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp16及其应用 |
CN201610109511.6A CN105541972A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp7及其应用 |
CN201610112187.3A CN105601716A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp11及其应用 |
CN201610107418.1A CN105622723A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp3及其应用 |
CN201610107546.6A CN105622724A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp8及其应用 |
CN201610113149.XA CN105541974A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp10及其应用 |
CN201410115439.9A CN103897037B (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽及其应用 |
CN201610107661.3A CN105541971A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp5及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410115439.9A CN103897037B (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽及其应用 |
Related Child Applications (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610109511.6A Division CN105541972A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp7及其应用 |
CN201610109158.1A Division CN105646661A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp2及其应用 |
CN201610110725.5A Division CN105541973A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp16及其应用 |
CN201610112193.9A Division CN105566455A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp13及其应用 |
CN201610109181.0A Division CN105646662A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp9及其应用 |
CN201610110770.0A Division CN105646663A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp4及其应用 |
CN201610112636.4A Division CN105646666A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp12及其应用 |
CN201610113149.XA Division CN105541974A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp10及其应用 |
CN201610112251.8A Division CN105646665A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp14及其应用 |
CN201610107546.6A Division CN105622724A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp8及其应用 |
CN201610112231.0A Division CN105601717A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp15及其应用 |
CN201610112187.3A Division CN105601716A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp11及其应用 |
CN201610107661.3A Division CN105541971A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp5及其应用 |
CN201610107418.1A Division CN105622723A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp3及其应用 |
CN201610111510.5A Division CN105646664A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp6及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103897037A CN103897037A (zh) | 2014-07-02 |
CN103897037B true CN103897037B (zh) | 2016-04-20 |
Family
ID=50988648
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610109511.6A Pending CN105541972A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp7及其应用 |
CN201610112187.3A Pending CN105601716A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp11及其应用 |
CN201610107661.3A Pending CN105541971A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp5及其应用 |
CN201610113149.XA Pending CN105541974A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp10及其应用 |
CN201610110725.5A Pending CN105541973A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp16及其应用 |
CN201410115439.9A Active CN103897037B (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽及其应用 |
CN201610107418.1A Pending CN105622723A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp3及其应用 |
CN201610107546.6A Pending CN105622724A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp8及其应用 |
CN201610112231.0A Pending CN105601717A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp15及其应用 |
CN201610112193.9A Pending CN105566455A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp13及其应用 |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610109511.6A Pending CN105541972A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp7及其应用 |
CN201610112187.3A Pending CN105601716A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp11及其应用 |
CN201610107661.3A Pending CN105541971A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp5及其应用 |
CN201610113149.XA Pending CN105541974A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp10及其应用 |
CN201610110725.5A Pending CN105541973A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp16及其应用 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610107418.1A Pending CN105622723A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp3及其应用 |
CN201610107546.6A Pending CN105622724A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp8及其应用 |
CN201610112231.0A Pending CN105601717A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp15及其应用 |
CN201610112193.9A Pending CN105566455A (zh) | 2014-03-24 | 2014-03-24 | 特异性结合前列腺癌的短肽pcp13及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (10) | CN105541972A (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002525382A (ja) * | 1998-09-25 | 2002-08-13 | ザ チルドレンズ メディカル センター コーポレイション | プロテインキナーゼの活性を選択的に調節するショートペプチド |
CN101033251A (zh) * | 2006-12-27 | 2007-09-12 | 华东师范大学 | 肝癌细胞特异性内在化短肽及其体外筛选和鉴定 |
CN101158687B (zh) * | 2007-06-11 | 2012-09-05 | 吉林大学 | 多肽psa2在制备前列腺癌诊断试剂盒中的应用 |
CN101928740B (zh) * | 2009-09-30 | 2013-01-30 | 西南交通大学 | Mmp14双靶点高效结合肽及多肽结构序列的获取和用途 |
CN101974069A (zh) * | 2010-10-22 | 2011-02-16 | 西南交通大学 | FoxM1c的DNA结合区蛋白高效结合肽及多肽结构序列的获取方法 |
CN102466729B (zh) * | 2010-11-05 | 2015-06-17 | 北京工业大学 | 一种基于组织芯片的肿瘤特异性靶点及靶向配体筛选方法 |
CN103882064B (zh) * | 2014-03-12 | 2016-03-23 | 清华大学 | 一种m13噬菌体介导的纳米铁还原镉离子的方法 |
-
2014
- 2014-03-24 CN CN201610109511.6A patent/CN105541972A/zh active Pending
- 2014-03-24 CN CN201610112187.3A patent/CN105601716A/zh active Pending
- 2014-03-24 CN CN201610107661.3A patent/CN105541971A/zh active Pending
- 2014-03-24 CN CN201610113149.XA patent/CN105541974A/zh active Pending
- 2014-03-24 CN CN201610110725.5A patent/CN105541973A/zh active Pending
- 2014-03-24 CN CN201410115439.9A patent/CN103897037B/zh active Active
- 2014-03-24 CN CN201610107418.1A patent/CN105622723A/zh active Pending
- 2014-03-24 CN CN201610107546.6A patent/CN105622724A/zh active Pending
- 2014-03-24 CN CN201610112231.0A patent/CN105601717A/zh active Pending
- 2014-03-24 CN CN201610112193.9A patent/CN105566455A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN105601717A (zh) | 2016-05-25 |
CN105622723A (zh) | 2016-06-01 |
CN105541972A (zh) | 2016-05-04 |
CN105601716A (zh) | 2016-05-25 |
CN105622724A (zh) | 2016-06-01 |
CN105541973A (zh) | 2016-05-04 |
CN105541974A (zh) | 2016-05-04 |
CN105566455A (zh) | 2016-05-11 |
CN103897037A (zh) | 2014-07-02 |
CN105541971A (zh) | 2016-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108409836B (zh) | 一种多肽及其用途 | |
WO2019205866A1 (zh) | 一种靶向人结肠癌细胞的特异性多肽 | |
WO2019154103A1 (zh) | 一种肿瘤靶向的新型多肽及其用途 | |
CN104650190A (zh) | 肝癌细胞表面特异性结合的多肽 | |
Lee et al. | Novel peptides functionally targeting in vivo human lung cancer discovered by in vivo peptide displayed phage screening | |
CN103897033A (zh) | 转铁蛋白受体TfR特异性结合肽及其应用 | |
CN103675294B (zh) | 新的肿瘤血清标志物及其应用 | |
CN101492505A (zh) | 一种肺癌特异性结合多肽及其制备方法和应用 | |
Xu et al. | Application of a single-chain fragment variable (scFv) antibody for the confirmatory diagnosis of hydatid disease in non-endemic areas | |
KR20140123311A (ko) | 암 표적용 펩타이드 및 이의 의학적 용도 | |
Zhang et al. | Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library | |
CN108059681B (zh) | 一种抗vegf及egfr的双特异抗体融合蛋白及其应用 | |
CN103897037B (zh) | 特异性结合前列腺癌的短肽及其应用 | |
Kenngott et al. | Identification of targeting peptides for mucosal delivery in sheep and mice | |
CN105987999A (zh) | 用于乳腺癌诊断的联合肿瘤标志物及其试剂盒 | |
CN107987168B (zh) | 一种抗vegf和egfr的单链双特异的抗体及其应用 | |
CN103788181B (zh) | 肺癌细胞特异性粘附短肽及其应用 | |
EP3611181A1 (en) | Atp1a1-targeting polypeptide and use | |
CN106967154B (zh) | 人结肠癌细胞特异性结合多肽的筛选方法及其应用 | |
CN108003239B (zh) | 一种全人源抗egfr单链抗体及其应用 | |
CN111018951B (zh) | 一种靶向三阴性乳腺癌细胞的多肽及其应用 | |
CN102466729A (zh) | 一种基于组织芯片的肿瘤特异性靶点及靶向配体筛选方法 | |
CN105646663A (zh) | 特异性结合前列腺癌的短肽pcp4及其应用 | |
CN105646661A (zh) | 特异性结合前列腺癌的短肽pcp2及其应用 | |
CN105646665A (zh) | 特异性结合前列腺癌的短肽pcp14及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160225 Address after: 315100 Zhejiang city of Ningbo province Yinzhou District east Wu Town Road No. 58 Applicant after: Zhu Yupan Address before: Yinzhou District Heng Jie Heng Jie Zhen Road 315181 No. 50 Zhejiang city of Ningbo Province Applicant before: Hua Guoguang |
|
DD01 | Delivery of document by public notice |
Addressee: Zhu Yupan Document name: Approval notice for cost mitigation Addressee: Zhu Yupan Document name: Notification of Passing Examination on Formalities |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Yixiong Inventor after: Zou Jie Inventor after: Cai Xiaolong Inventor before: Hua Guoguang |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170320 Address after: 201203 Shanghai Zhangjiang High Tech Park of Pudong New Area Cailun Road No. 150 Building 1 floor 2 Patentee after: Han Heng biotechnology (Shanghai) Co., Ltd. Address before: 315100 Zhejiang city of Ningbo province Yinzhou District east Wu Town Road No. 58 Patentee before: Zhu Yupan |
|
TR01 | Transfer of patent right |